Hikma Pharmaceuticals, a leading multinational pharmaceutical group, will join the FTSE 100 Index, comprising the 100 most highly capitalised blue chip companies listed on the London Stock Exchange, as of March 24.
Mazen Darwazah,

Hikma Pharmaceuticals, a leading multinational pharmaceutical group, will join the FTSE 100 Index, comprising the 100 most highly capitalised blue chip companies listed on the London Stock Exchange, as of March 24.
Mazen Darwazah,

Hikma Pharmaceuticals, a major multinational pharmaceutical group with operations across Mena, Europe and the US, reported a 16 per cent increase in Group revenue to $738 million during first six months of the year.
The increase i

Hikma Pharmaceuticals, a top multinational pharmaceutical group, has reported revenue of $638.3 million in the first half of 2013, reflecting a 19.9 per cent increase over the same period last year.
The Group is expected to delive

London-listed Hikma Pharmaceuticals plans to spend nearly $300 million on acquisitions and expansion initiatives in 2012 amid strong growth prospects in the Middle East and North Africa, its chief financial officer said.
"In terms of acqui

Jordanian pharma company Hikma saw its first-half revenue surge 10.4 per cent despite problems in other North African and Middle East markets due to a strong sales in Algeria, Sudan and Iraq.
Hikma, which sells both generic and b

Jordanian drugmaker Hikma Pharmaceuticals said it expected first-half revenue to grow around 40 per cent.
Hikma also said in a trading update, ahead of the release of results for the first half of 2007 on September 5, it was confident of d